Clinical

Dataset Information

0

Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer


ABSTRACT: This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning. LOAd703 is administered by intratumoral image-guided injections. Maximum 50 patients can be enrolled. LOAd703 is an immunostimulatory gene therapy using an selection replication competent adenovirus as a gene vehicle. The virus is derived from serotype 5 adenovirus with the fiber from serotype 35. It expresses the transgenes trimerized membrane-bound isoleucine zipper (TMZ) TMZ-CD40L and 41BBL under control of a cytomegalovirus (CMV) promoter.

DISEASE(S): Ovarian Cancer,Colorectal, Ovarian, Pancreatic, Gallbladder And Bile Duct Cancer,Pancreatic Adenocarcinoma,Colorectal Cancer,Cancer,Biliary Carcinoma

PROVIDER: 2249969 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2018-10-22 | PXD008022 | Pride
2018-10-22 | PXD008023 | Pride
| PRJNA92727 | ENA
2015-12-10 | GSE54772 | GEO
2015-12-10 | E-GEOD-54772 | biostudies-arrayexpress
| PRJNA20997 | ENA
2020-10-13 | GSE144784 | GEO
2013-06-03 | E-GEOD-44122 | biostudies-arrayexpress
2015-01-29 | E-GEOD-65363 | biostudies-arrayexpress
2014-09-01 | GSE58605 | GEO